IMUX Immunic Inc. Forecast, Technical & Fundamental Analysis
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more
IMUX is expected to report earnings to rise 47.50% to -117 cents per share on November 05
Q3'26
Est.
$-1.18
Q2'26
Beat
by $0.43
Q1'26
Missed
by $1.00
Q4'25
Missed
by $0.53
Q3'25
Beat
by $0.02
The last earnings report on August 11 showed earnings per share of -80 cents, beating the estimate of -123 cents. With 73.28K shares outstanding, the current market capitalization sits at 174.10M.
A.I. Advisor
published General Information
General Information
a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases
A.I.dvisor indicates that over the last year, IMUX has been loosely correlated with ERAS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if IMUX jumps, then ERAS could also see price increases.
IMUX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 27, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMUX as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
IMUX moved below its 50-day moving average on September 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IMUX crossed bearishly below the 50-day moving average on September 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMUX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for IMUX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMUX advanced for three days, in of 262 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMUX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 159 cases where IMUX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.365) is normal, around the industry mean (20.490). P/E Ratio (0.000) is within average values for comparable stocks, (28.270). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.510). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (444.384).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMUX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMUX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
